艾媒咨询|2021年9月中国医疗健康行业投融资数据分析报告

人口老龄化，人均GDP、人均收入的提升，同时也带来了人们健康需求的增长。近年来，医疗健康产业创新不断涌现，并发展成为最活跃的行业之一，相关细分赛道也维持着较高的增长，收获了资本市场的大量关注。
艾媒咨询通过艾媒数据中心(data.iimedia.cn)查询并发布《2021年9月中国医疗健康行业投融资数据分析简报》，助力投资人与创业者用户即时了解市场趋势，获取关键投资决策所需的数据，把握投资逻辑和最新产业机会。(《艾媒咨询|2021年9月中国医疗健康行业投融资数据分析报告》完整高清PDF版共21页，可点击文章底部报告下载按钮进行报告下载)
The aging of population and the increase of per capita GDP and per capita income have also brought about the growth of people's health demand. In recent years, the innovation of medical and health industry has been emerging and developed into one of the most active industries. The relevant segments have also maintained high growth and gained a lot of attention from the capital market.
Iimedia inquires and publishes the analysis briefing on investment and financing data of “China's medical and health industry in September 2021 through iimedia data center (data. Iimedia. cn), so as to help investors and entrepreneurs understand the market trend in real time, obtain the data required for key investment decisions, and grasp the investment logic and the latest industrial opportunities.(“iiMedia Report |Analysis report on investment and financing data of China's medical and health industry in September 2021”full version has 21 pages in total, please click the Browse HD Report button on the right side of the article to browse the report)

艾媒咨询|2021年中国医美机构市场竞争态势及企业营销模式分析报告

本报告研究涉及企业/品牌/案例：华韩整形，瑞丽医美，美莱整形，医思健康

数据显示，2016—2020年中国医美行业市场规模五年平均增长率为12.8%，与此同时，中国医美市场用户规模增长了4倍多。在人们生活水平的提升、年轻一代对医美的接受度的提高、政府监管层对医美行业的整治给医美消费者信心的提升的综合作用下，预计中国医美市场规模在2022年将达到2232亿元。随着医美产品及仪器技术水平提升、医美知识普及等，民众对整形美容的观念正在向积极态度转变，在整个行业扩张的过程中，轻医美的受众面广、门槛低、复购率高，更有可能提升市场整体渗透率，成为我国医美行业的主要增量市场。
According to the data, from 2016 to 2020, the five-year average growth rate of the market scale of China's medical and American industry was 12.8%. At the same time, the user scale of China's medical and American market increased by more than four times. Under the combined effect of the improvement of people's living standards, the improvement of the acceptance of medical beauty by the younger generation, the regulation of the medical beauty industry by the government regulators and the improvement of medical beauty consumer confidence, it is expected that the scale of China's medical beauty market will reach 223.2 billion yuan in 2022. With the improvement of the technical level of medical beauty products and instruments and the popularization of medical beauty knowledge, people's concept of plastic beauty is changing to a positive attitude. In the process of the expansion of the whole industry, light medical beauty has a wide audience, low threshold and high repurchase rate, which is more likely to improve the overall penetration rate of the market and become the main incremental market of China's medical beauty industry.

2012-2013年中国移动医疗市场年度报告

本报告是由艾媒咨询行业分析专家领衔撰写，主要分析了该行业的市场规模、发展现状与投资前景，同时对该行业的未来发展作出科学的趋势预测和专业的行业数据分析，帮助客户评估该行业的投资价值。

艾媒咨询｜2022年中国幽门螺旋杆菌检测市场专题调查报告

美国将幽门螺杆菌被列为明确致癌物后，幽门螺杆菌在中国受到了极大的关注。iiMedia Research（艾媒咨询）数据显示，2021年中国幽门螺杆菌检测市场规模73.1亿元，预计2022年将达到86.6亿元。艾媒咨询分析师认为，随着大众的健康意识逐渐加强，幽门螺杆菌自测产品将成为必需品，幽门螺杆菌检测市场发展空间广阔。而幽门螺杆菌自测产品的上市，有助于推动居家检测。(《艾媒咨询｜2022年中国幽门螺旋杆菌检测市场专题调查报告》完整高清PDF版共23页，可点击文章底部报告下载按钮进行报告下载)
After the United States Department of Health & Human Services listed Helicobacter pylori as a definitive carcinogen, Helicobacter pylori received great attention in China. According to data from iiMedia Research, the market size of Helicobacter pylori testing in China will be 7.31 billion yuan in 2021 and is expected to reach 8.66 billion yuan in 2022. With increasing health awareness, Helicobacter pylori self-test product is necessary for people. The market for Helicobacter pylori self-test product is vast. The launch of Helicobacter pylori self-test products helps to promote home testing.（“iiMedia Report ｜Investigation Report on The Market of Helicobacter Pylori Testing in China in 2022”full version has 23 pages, please click the Browse HD Report button on the right side of the article to browse the report）

艾媒咨询|2021年中国轻医美行业研究及产业链分析报告

本报告研究涉及企业/品牌/案例：爱美客，华熙生物，奇致激光，华韩整形，新氧，兰州生物

数据显示，2020年中国轻医美用户市场规模达到1520万人，预计到2021年将增至1813万人。在消费意识觉醒和消费需求驱动下，机构、医生在供给端强势助推轻医美行业更快速发展，预计2021年中国轻医美市场将达到798亿元，同比增长46.4%。在行业快速增长的同时，轻医美产业链各环节企业由于集中度不同导致利润分配不均，具体来看，上游原料耗材企业由于高技术壁垒，市场集中度较高，毛利率高于中下游企业，如知名玻尿酸、肉毒素产品制造企业爱美客、华熙生物等，而中下游由于竞争分散，单体获利参差不齐，更容易产生乱象。但总体来说，在行业监管加强、机构自律、平台监督等多方力量共同作用下，轻医美行业将会向线上化、品牌化、规范化发展。
According to the data, the market size of China's light medical beauty users will reach 15.2 million in 2020, and it is expected to increase to 18.13 million by 2021. Driven by the awakening of consumer awareness and consumer demand, institutions and doctors strongly boost the rapid development of light medical beauty industry in the supply side. It is estimated that China's light medical beauty market will reach 79.8 billion yuan in 2021, with a year-on-year growth of 46.4%. With the rapid growth of the industry, the profit distribution of enterprises in each link of the light medical beauty industry chain is uneven due to different concentration. Specifically, due to high technical barriers, the upstream raw materials and consumables enterprises have higher market concentration and higher gross profit rate than the middle and downstream enterprises, such as the well-known hyaluronic acid, botulinum toxin product manufacturing enterprises aimekke, Huaxi biology, etc., while the middle and downstream enterprises have higher gross profit rate due to scattered competition, Individual profit is uneven, more likely to produce chaos. But on the whole, under the joint action of industry supervision, institutional self-discipline, platform supervision and other forces, the light medical beauty industry will develop to online, brand and standardization.

艾媒报告 |2018-2019中国医疗美容行业研究与产业链分析报告

本报告研究涉及企业/品牌包括:新氧、更美、悦美、美黛拉、美丽神器、美呗、南方医院、伊美尔、熙朵、碧莲盛、雍禾植发、科发源植发、新生植发、恒博医疗、昊海生物科技、华熙生物、复星医药、深圳鹏爱医疗美容医院、北京丽都医疗美容医院

中国医疗美容行业处于快速发展期，iiMedia Research（艾媒咨询）监测发现，2018年中国医美行业市场规模达2245亿元，牙齿美容及面部美容是医美市场的重要构成部分，占比分别达32.5%和35.3%。目前中国医美行业已形成生产商、医美机构、终端市场三大产业链环节，产业发展前景广阔，但作为新兴行业，中国医疗美容行业将面临着行业监管、公共关系危机、行业竞争激烈等几大风险。

Driven by the rise of the younger generation of consumer groups and the development of new models in the medical beauty industry, the penetration rate and consumer demand of China's medical beauty industry continue to rise. In 2018, the penetration rate of Chinese medical users reached 7.4%, and women were the main medical and aesthetic consumers. The proportion is 88.9%. At present, there are more than 10,000 registered medical and beauty institutions in China, and the industry is in a period of rapid development. iiMedia Research found that embedding, double eyelids, and full body fat filling are the favorite surgical items for Chinese women and medical consumers, while nasal synthesis, tautological fat, cheeks, hair transplants, etc. For the Chinese male medical beauty consumer's favorite surgical project, potential customers in China's medical beauty industry are most concerned about the safety of surgery, followed by medical qualifications and word of mouth and surgery prices. Medical beauty as an emerging industry, public relations crisis, strict industry supervision, lack of relevant professionals is a factor that restricts its development, and in the future, with the influx of capital from the industry, the competition in China's medical and aesthetic industry will become more intense.

艾媒咨询｜2022-2023年全球与中国大健康产业运行大数据及决策分析报告

随着人们对健康的关注度和需求度的逐渐上升，大健康产业已经成为全球热点和新的经济增长点。大健康产业顺应了中国经济转型升级、绿色发展的趋势，全球医疗健康产业投融资金额最多集中在2021年，全年达到6846.03亿元，投融资数量最多在2019年，达2044起。

艾媒咨询 | 2025年中国医美行业发展状况与消费行为调查数据

随着消费升级与技术迭代，中国医美行业已从传统整形扩展至轻医美、抗衰老等多元化领域，市场规模持续扩大。根据全球领先的新经济产业第三方数据挖掘和分析机构iiMedia Research（艾媒咨询）最新发布的《2025年中国医美行业发展状况与消费行为调查数据》显示，2025年中国医美服务行业市场规模为3701亿元，2025年中国轻医美市场用户规模达3105万人。中国医美市场的增长不仅源于消费升级，也得益于技术普惠与轻医美项目的高复购率。当前行业已进入以精细化运营、差异化服务和合规化发展为核心驱动的新阶段。
在2025年中国消费者对医美项目的接受程度中，“会考虑整形，但风险要相对可控”位列第一，占比46.02%；其次是“能够接受手术医美整形，并承受一定风险”，占比22.94%。此外，在消费者接受过的医美项目中，轻医美（非手术类）占比最高，达到74.45%；医美整形（手术类）的占比为33.52%。这表明中国消费者对医美的态度趋于理性与谨慎，安全可控的非手术类项目成为市场主流偏好。同时，手术类项目亦拥有稳定的需求群体，显示出市场需求的层次性与多元化。
艾媒咨询分析师认为，未来中国医美市场将延续“轻医美主导、技术驱动、合规深化”的主线发展。一方面，非手术项目凭借低风险、高复购优势，仍是增长核心，Z世代与男性、下沉市场需求进一步释放。另一方面，再生材料、AI个性化方案及智能器械加速迭代，推动服务精准化与效果革新。此外，监管常态化下，行业加速品牌化整合，合规机构与上游技术型企业凸显优势。总的来说，消费者更趋理性，追求自然效果与安全保障，倒逼市场从营销竞争转向以品质、精细化运营为核心的高质量发展新阶段。
With the upgrading of consumption and technological advancements, China's medical aesthetics industry has expanded from traditional plastic surgery to diversified fields such as minimally invasive aesthetics and anti-aging. The market size has continued to grow. According to the latest "2025 China Medical Aesthetics Industry Development Status and Consumer Behavior Survey Data" released by iiMedia Research, a leading third-party data mining and analysis institution for the new economy industry, the market size of China's medical aesthetics service industry will reach 370.1 billion yuan in 2025, and the user scale of the minimally invasive aesthetics market in China will reach 31.05 million people in 2025. The growth of China's medical aesthetics market is not only due to the upgrading of consumption but also benefits from the popularization of technology and the high repurchase rate of minimally invasive aesthetics projects. Currently, the industry has entered a new stage driven by refined operation, differentiated services, and compliance development.
In terms of Chinese consumers' acceptance of medical aesthetics projects in 2025, "Would consider plastic surgery, but the risk should be relatively controllable" ranks first, accounting for 46.02%; followed by "Can accept surgical medical aesthetics and bear certain risks", accounting for 22.94%. Additionally, among the medical aesthetics projects consumers have received, minimally invasive aesthetics (non-surgical) accounts for the highest proportion, reaching 74.45%; surgical medical aesthetics accounts for 33.52%. This indicates that Chinese consumers' attitudes towards medical aesthetics are becoming more rational and cautious, and non-surgical projects with low risks and high repurchase rates have become the mainstream preference in the market. At the same time, surgical projects also have a stable demand group, demonstrating the hierarchical and diversified nature of market demand.
Analysts from iiMedia Research believe that in the future, China's medical aesthetics market will continue to develop along the main line of "minimally invasive aesthetics dominance, technology-driven, and compliance deepening". On the one hand, non-surgical projects, with their low-risk and high-repurchase advantages, will remain the core of growth, and the demands of Generation Z, men, and consumers in lower-tier cities will be further released. On the other hand, regenerative materials, AI personalized solutions, and intelligent devices will accelerate iteration, promoting the precision and effect innovation of services. Moreover, under the normalization of regulation, the industry will accelerate brand integration, and compliant institutions and upstream technology enterprises will highlight their advantages. In summary, consumers are becoming more rational, pursuing natural effects and safety guarantees, which will force the market to shift from marketing competition to high-quality development centered on quality and refined operation.

和佳医疗：2021年第三季度报告

艾媒报告丨2016-2017中国移动医疗健康市场研究报告

iiMedia Research(艾媒咨询)数据显示，iiMedia Research(艾媒咨询)数据显示，中国移动医疗健康市场用户规模稳步增长，2016年第四季度接近3.0亿，与2015年相比，增长16.0%。